Search

Search Constraints

You searched for: Author/Creator Morano, F

Search Results

1. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. (10th March 2018)

2. PD-016Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study. (2nd July 2019)

3. LBA-007Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC. (2nd July 2019)

4. LBA22Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study. (23rd October 2018)

5. O-016First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (20th June 2018)

6. PD-017Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC). (20th June 2018)

7. PD-008Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting. (20th June 2018)

8. PD-008Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting. (20th June 2018)

9. O-016First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (20th June 2018)

10. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. Issue 12 (December 2022)